A class of diabetes and weight loss drugs that includes Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could also help protect against a variety of cancers, according to new research published Friday, adding to mounting evidence the injections offerGlucagon-like peptide receptor agonists, a class of drugs often known as GLP-1s or GLP-1RAs, were associated with a “significant risk reduction” for 10 different cancers when used to treat type 2 diabetes compared to insulin, according to...
GLP-1 drugs, which mimic the action of a gut hormone and can help control blood sugar, include popular obesity and diabetes treatments like Ozempic and Wegovy , Mounjaro and Zepbound , Victoza and Saxenda and Trulicity . All of the 13 cancers studied are considered obesity-associated cancers as excess body fat has been linked to a greater risk of developing them and worse prognosis among patients who do.